- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02820662
Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in New-born Infants (OMEGAROP)
May 6, 2019 updated by: Centre Hospitalier Universitaire Dijon
Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in Newborns
The development of the retinal vascular network is generally complete during the 3rd trimester of pregnancy but may continue during the first 15 days of life.
This late maturation may cause problems in pre-term births and may result in immature vascularization of the retina, a condition called retinopathy of prematurity.
Among the different factors affecting the development of the retinal vasculature, the tissue level of omega-3 polyunsaturated fatty acids (PUFA) appears to be a crucial element, as does the form of the PUFA present in the tissues (nature of the phospholipids in their membranes).
This project aims to show a possible association between levels of omega-3 PUFA and the onset of retinopathy of prematurity (ROP).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dijon, France, 21079
- Centre Hospitalier Universitaire
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 4 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Premature new-born infants born at less than 29 weeks of amenorrhea after informed consent has been obtained from a parent or the legal guardian of the infant
Exclusion Criteria:
- Premature new-born infants presenting a life-threatening condition. Persons without national health insurance cover
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RETCAM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Stage of retinopathy of prematurity using a Retcam according to the ICROP classification (International Classification of Retinopathy of Prematurity) revised in 2005.
Time Frame: At 4 weeks of life or 31 weeks of amenorrhea
|
At 4 weeks of life or 31 weeks of amenorrhea
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentrations of omega-3 PUFA in Red Blood Cell (RBC) membranes.
Time Frame: At inclusion
|
At inclusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 30, 2015
Primary Completion (Actual)
May 31, 2018
Study Registration Dates
First Submitted
June 29, 2016
First Submitted That Met QC Criteria
June 30, 2016
First Posted (Estimate)
July 1, 2016
Study Record Updates
Last Update Posted (Actual)
May 8, 2019
Last Update Submitted That Met QC Criteria
May 6, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KOEHRER APJ 2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinopathy of Prematurity
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedRetinopathy of Prematurity (ROP)United States
-
Novartis PharmaceuticalsCompletedRetinopathy of Prematurity (ROP)United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United Kingdom, Lithuania, Estonia
-
ShireCompletedRetinopathy of Prematurity (ROP)United States, Italy, Netherlands, Poland, Sweden, United Kingdom
-
BayerRegeneron PharmaceuticalsCompletedAflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)Retinopathy of Prematurity (ROP)Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
-
University Hospital FreiburgCompletedRetinopathy of Prematurity (ROP)Germany
-
Zagazig UniversityCairo UniversityRecruitingRetinopathy of Prematurity Both EyesEgypt
-
ShireCompletedRetinopathy of Prematurity (ROP)United States, Italy, Netherlands, United Kingdom, Sweden, Poland
-
University Hospital FreiburgWithdrawn
-
BayerRegeneron PharmaceuticalsActive, not recruitingRetinopathy of Prematurity (ROP)Spain, Korea, Republic of, Singapore, Malaysia, Japan, Taiwan, Bulgaria, Italy, Argentina, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Sweden, Turkey, United Kingdom, Ukraine, Belgi...
-
Georgetown UniversityCompleted
Clinical Trials on Blood samples
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Institut BergoniéUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
Centre Hospitalier Universitaire de NīmesCompletedHenoch Schönlein PurpuraFrance
-
Centre Georges Francois LeclercCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Assistance Publique Hopitaux De MarseilleRecruitingPlastic SurgeriesFrance
-
University Hospital, BordeauxRecruitingSystemic Sclerosis | SclerodermaFrance
-
Centre Hospitalier Universitaire, AmiensCompleted